Introduction
Designing of controlled-release drug delivery systems is a promising and rapidly developing line of modern pharmacology (Amass et al., 1998) . Drug delivery systems in the form of biodegradable microspheres and microcapsules can be injected subcutaneously, intramuscularly and into the bloodstream (Freiberg et al., 2004) .
Drug delivery systems intended for intravenous injection must be not only biocompatible but also hemocompatible, i.e. the materials used to construct them must not induce thromboses, thromboembolisms, antigenic response or destruction of blood constituents and plasma proteins; they must also retain their mechanicalphysical properties (Yen et al., 2003; Kim et al., 2004) .
Bioresorbable polyesters of microbiological origin -polyhydroxyalkanoates (PHAs) -are considered to be promising materials to be used as scaffold carriers for drug delivery (Amara et al., 2008) . Polyhydroxybutyrate was used as a basis for production of polymer scaffold constructions in the form of films, tablets, and microparticles (Sevastianov et al., 2003; Shishatskaya et al., 2006) ; it was proved that PHB microparticles were highly biocompatible and could be injected intramuscularly (Shishatskaya et al., 2008a) ; experiments with PHB scaffolds loaded with rubomycin hydrochloride showed their suitability as carriers of anticancer drugs (Shishatskaya et al., 2008b) . It should be mentioned that today the number of PHA studies devoted to the development of controlled-release systems is considerably less than the number of similar studies based on biodegradable polylactides and polyglycolides.
Today antibiotics, hormonal agents and anticancer drugs in the form of microparticles can be deposited into PHA matrices (Abe and Doi 1992; Kassab et al., 1997; Lionzo et al., 2007; Wang et al., 2007; Bazzo et al., 2008) . PHA biocompatibility was proven in vitro using cells of different origins (Choi et al., 2005) and in in vivo experiments (Gogolewski et al., 1993; Qu et al., 2006) .
However, despite the existing data about using PHAs for the microencapsulation of drugs, the problem of biocompatibility of polymer particles as carriers for drugs to be administered intravenously is not covered in the available literature. One of the earliest investigations devoted to the possible intravenous administration of PHA microparticles was performed by Bissery et al., 1984 . Using the method of solvent evaporation from the 14 C-labeled PHB solution, microspheres were obtained with the diameter of 1-12 µm and injected intravenously to mice; after the injection the microspheres were localized mainly in lungs. However, introduction of these microspheres loaded with the anticancer agent, lomustine, to Levis' mice infected with carcinoma had minimal effect. In addition, the location of 14 C-labeled polyhydroxybutyrate granules was investigated with the intravenous injection (Saito et al., 1991) .
E.T. Baran and co-authors (2002) studied the toxicity and half life of encapsulated L-asparaginase (ASNase) in poly (3-hydroxybutyrate-co-3- hydroxyvalerate) PHBV nanocapsules in mice.
The PHBV nanocapsules with heparin conjugated on their surface had a longer presence in the circulation than unmodified PHBV nanocapsules.
No adverse effects were observed upon injection of encapsulated ASNase-PHBV nanocapsules to mice i.v. through the tail vein.
The purpose of this study was to examine the distribution of PHB microparticles in the internal organs of laboratory animals; biocompatibility of PHB microparticles and their life-time in the organism after intravenous injection; distribution dynamics of microparticles and degradation products in the internal organs of laboratory animals. Chloroform was used as an eluent at a flow rate of 0.8 ml/min, and a sample concentration of 1.0 mg/ml was used. Polystyrene standards were used to construct a calibration curve.
Materials and methods

Preparation of 14 C-labeled PHB polymer
For determination of the crystallinity degree, Сх, scan-step spectra were read off, with sensitivity 0.04°, and a 2-second optical exposure for determination of intensity at a certain point (the device functioning mode was 40 kW х 40 mkА). The IR-spectra of absorption of the PHA film samples were registered using the IR Fourier spectrometer INFALUM FT-02 (Lumex, Russia). Microspheres were collected by centrifuging (at 10000 rpm, for 5 min), rinsed 7-8 times in distilled water, and freeze-dried in the LS-500 lyophilizer (Prointex, Russia).
Preparation of microspheres
Microsphere characterization
The size of microspheres with a diameter bigger than 3 µm was determined using the Automatic Particle Counter + Analyser system (Casy TTC, Scharle System GmbH, Germany).
The obtained size distribution was used to describe the particle size.
For intravenous injections a fraction of
microspheres with a diameter smaller than 3.8 mkm was selected, using a treck filter. The size of particles was estimated using the Scan master program of the scanning multimicroscope CMM-2000 taking into account the parameters which determined the image size. The structure of microsphere surfaces was analyzed by electron microscopy, as was described previously (Shishatskaya et al., 2008a) .
Animal model
Experiments were conducted on adult female Radiocarbon was measured in the heart, lungs, liver, kidneys, bone marrow, and blood, without taking into account the radioactivity of soft and hard tissues and excreted metabolic products. To study the resorption of the polymer scaffold and accumulation of 14 C-containing PHA degradation products, samples of the dried tissues were subjected to methanolysis, and fatty acid methyl esters were determined using the GCD plus chromatograph mass spectrometer (Hewlett Packard, USA). To determine high-molecularweight (undecomposed) polymer in the organs, it was extracted from the tissues with chloroform and precipitated with hexane. Then the polymer was methylated and chromatographed as described above; the sensitivity was 10-11 g. The general tissue reaction to implanted microspheres was investigated using conventional histological techniques. The samples were fixed in 10 % formalin and embedded in paraffin; 5-10 μm thick microtome sections were stained with hematoxylin and eosin.
Statistics
The results were analyzed statistically using the standard software package of Microsoft 
Results
Microspheres characterization
The microspheres were of regular spherical shape and had a well-developed «wrinkled» surface; their diameters were significantly heterogeneous. 
Distribution of PHB microparticles in internal organs
All animals that had been injected with a microspheres suspension were healthy and ate The level of radioactivity in blood and bone marrow did not exceed 300 cpm/g. Thus, the tissues of internal organs sorbed different amounts of intravenously injected microparticles. This is even more obvious from the analysis of the data in (Fig. 3) , which
shows in vivo accumulation of the label, taking into account the masses of the organs. Data During the period of microparticle circulation a reliable decrease in the organ radioactivity was detected, which we believe is due to the initiated process of polymer matrix biodegradation and excretion of the label part with carbon-containing PHB biodegradation products. Thus, three hours after the injection of microparticles to the animals, the total radioactivity of the organs was 38720 ± 2575 cpm/g, i.e. 80 % of the radioactivity of the injected dose (Fig. 4) . 120 days after the intravenous injection the total radioactivity dropped to 28210 ± 2054 cpm/g, which can be attributed to polymer biodegradation.
PHB biodegradation in internal organs
We should note here that the registered amounts of radiocarbon in the rats' organs do not
show the true accumulation of microparticles in the organs: PHAs are biodegradable polyesters and are bioresorbed in vivo by the enzymes (Table 2) . One week after the injection, the polymer content registered in Fig. 4 . Dynamics of total 14 C radioactivity in animal organism the lungs, heart, and liver was larger than that registered in the spleen and kidneys. Eight weeks after the injection, the polymer content in the lungs and heart dropped dramatically (similarly to the data of Table 1 ), but that was rather due to particle washout than degradation processes. This conclusion was confirmed by the measurements of tissue radioactivity. It should be noted that the data at the end of a 12 week interval given in tables 1 and 2 differ significantly: chromatography of the tissues determined much higher amounts of the polymer substance (Table 1 ) than the amounts of the high-molecular-weight polymer recovered from the organs (Table 2 ). This leads to the conclusion that at the end of the experiment, the major portion of the 14 C-labeled polymer was present in vivo as monomers of hydroxybutyric acid and its low-molecular-weight degradation products.
The second important conclusion based on the data of Table 2 is that some polymer microparticles remained undecomposed in the animals' organs at different time points of the experiment. Finally, the fact that the examined organs, especially the liver and the spleen, contained relatively low amounts of the polymer, while radioactivity of the tissues was high, is indicative of the rapid degradation of the polymer scaffold in them.
Discussion
In this paper, we have presented the results of investigation into the distribution of intravenously injected 14 C-labeled polymer (PHB) microparticles in internal organs of laboratory animals and the localization of PHA biodegradation products.
There is substantial literature data on the in vitro and in vivo kinetics of drug release from polymer matrices, their medicinal effectiveness, and the possibilities of targeted delivery (Arulsudar et al., 2003; Petri et al., 2007; Bazzo et al., 2008) . However, there are rather few studies that describe investigations of the in vivo distribution and dynamics of infused microparticles, especially PHA-based ones, although this aspect is obviously very important. Distribution of microparticles and the rates of their elimination from the body depend on many factors, and the available literature data on mechanisms of biodistribution are contradictory.
Most authors report that the main targets of intravenously injected particles are the organs of the reticuloendothelial system, namely the liver and the spleen (Owens et al., 2006) . In one of the first published studies devoted to this subject it was reported that the distribution of 141 C-labeled polystyrene/divinylbenzene microparticles intravenously injected to dogs depended on the size of the particles and that particles of a larger diameter were taken up by the organs at a higher rate (Kanke et al., 1980) . Microspheres Bissery and co-authors studied distribution of microspheres based on 14 C-labeled PHB, and 1-12 µm microspheres intravenously injected to mice were mostly found in the lungs (Bissery et al., 1984) . Another distribution pattern was observed for smaller (0.3-0.5 µm) PHB particles injected to rats via the tail vein -at 2.5 h 86 % of radioactivity was registered in the liver, and the lungs and the spleen contained 2.5 % each (Saito et al., 1991 (Bissery et al., 1984; Ballot et al., 2006) .
The comparison of degradation of microparticle polymer scaffold in different organs showed that PHB is resorbed at the highest rate in the spleen and liver. In addition, at 12 weeks we observed undecomposed microparticles, which led us to the conclusion that PHB particles can be used as sustained drug delivery systems.
In conclusion, this study shows that polyhydroxybutyrate microparticles are suitable for intravenous administration; tissues of internal organs accumulate different concentrations of polymer microparticles, and polymer scaffold is degraded in them at different rates. The presence of high-molecular-weight polymer scaffold registered in internal organs, which is indicative of microparticles remaining undecomposed, suggests that polyhydroxybutyrate can be used to construct systems for sustained (up to 12 weeks) drug delivery to tissues of internal organs via intravenous administration.
